Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.
about
Treating refractory leukemias in childhood, role of clofarabineChildhood acute myeloid leukaemiaEfficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia.High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.Immune-based therapeutics for pediatric cancer.Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.Immunotherapy of childhood cancer: from biologic understanding to clinical application.Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemiaTreatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.Molecular profiling of childhood cancer: Biomarkers and novel therapiesThe role of gemtuzumab ozogamicin in acute leukaemia therapy.Advances in the treatment for haematological malignancies.The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients.Immunotherapy for pediatric leukemia.Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies.Infectious complications associated with monoclonal antibodies and related small moleculesNovel targeted drug therapies for the treatment of childhood acute leukemiaMolecular therapeutic approaches for pediatric acute myeloid leukemia.Antibody therapy for pediatric leukemia.Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.The future role of monoclonal antibody therapy in childhood acute leukaemias.Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments.Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.Novel approaches to pediatric leukemia treatment.Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia.Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia.Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality.Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531.Advances in immunotherapy for pediatric acute myeloid leukemia.
P2860
Q24647279-5AFA3A97-8337-4D3D-968C-0F3FE12670ABQ27005960-0092FC76-CECE-4966-9025-D062499AFC99Q33248188-818718EF-302B-4B02-862B-B0E562216918Q33373033-3EA95AC9-90E2-4D90-B55B-A091ACA0AAEBQ33604121-36C27E66-855B-4B5A-9C04-01AFB6891FD8Q33729158-F1008E69-BF60-4A8E-A377-AA63FCCB1BF2Q33752982-96AA0287-4995-4563-8880-1430158D153EQ34172042-9A2D5502-810A-4488-806A-118E99E3039AQ34742630-C4F3D5BD-ABDB-4550-8091-E57DE1741AC0Q35446333-5EA267C3-F5AA-4C03-BBC2-3AECBE0B7F6CQ35909648-E9A15366-9E41-4A14-9D91-46661C66D09CQ36022701-F78B7B1D-84F7-4943-8C95-BA4966D6FDF6Q36250783-E58FCF4E-BFF4-48A4-971A-3B34BE556226Q36367816-879EC18D-33A1-4E05-8CF6-2FAB1C06C563Q36429723-75281BCF-8B8E-40E7-B26B-2CF70B22B634Q36832124-1D1DA3A3-B968-45C5-BB29-CD2F17AF5C33Q36968163-2BD032A5-5530-4F89-BDF0-322E91141187Q36997723-05FD4DC2-0555-4396-A72A-C78CA645C419Q37156636-E3F1AE27-0336-4D4D-A3CB-9FBAEEBD41FBQ37477482-F2C8787C-3250-4269-B7A9-7889EA5CD934Q37643136-26E2D5F3-D0D2-45D3-89AE-4982F0B8FE10Q37725578-3A29E4FE-1347-4289-BA96-3E386CE39275Q38025158-F64ABE25-0BE3-4D71-AC50-DF594C4C8051Q38033600-349CAC1A-148B-4A1C-8027-9251F1C9175AQ38109541-06FE80D2-4FDB-43EC-A8BE-334492471783Q38155455-E96846CD-769C-4E4E-AB6A-55161F587733Q38196743-5F9BA658-52F1-459D-9B33-05A6ABDDDDD3Q38500371-475D49F7-8397-4B50-AA7B-24943C5B6FBBQ38662393-1503C675-D62F-407B-8380-E98926E648EAQ41087485-F43ABD2B-4BE5-4173-AC7F-7F40F92FE601Q43096291-859B3430-A54D-483E-BFAD-19592F60E72FQ46278883-24E157A5-73FF-48F6-99E1-2B84BD83EE76Q47930962-CEDEA6C0-44CF-4265-A5C7-B4F3BFD9AAE6
P2860
Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Safety and efficacy of gemtuzu ...... CD33+ acute myeloid leukemia.
@en
Safety and efficacy of gemtuzu ...... CD33+ acute myeloid leukemia.
@nl
type
label
Safety and efficacy of gemtuzu ...... CD33+ acute myeloid leukemia.
@en
Safety and efficacy of gemtuzu ...... CD33+ acute myeloid leukemia.
@nl
prefLabel
Safety and efficacy of gemtuzu ...... CD33+ acute myeloid leukemia.
@en
Safety and efficacy of gemtuzu ...... CD33+ acute myeloid leukemia.
@nl
P2093
P1433
P1476
Safety and efficacy of gemtuzu ...... CD33+ acute myeloid leukemia.
@en
P2093
Beverly Lange
David Flowers
Eric L Sievers
Franklin O Smith
Irwin Bernstein
Jane Sande
Janet Franklin
Kevin Shannon
Mark S Berger
Matthew L Sherman
P304
P356
10.1182/BLOOD-2004-10-3821
P407
P577
2005-05-10T00:00:00Z